Genes raise Alzheimer risk in some women: Study | WeForNews | Latest News, Blogs Genes raise Alzheimer risk in some women: Study – WeForNews | Latest News, Blogs
Connect with us

Health

Genes raise Alzheimer risk in some women: Study

Published

on

Alzheimer

New Delhi, Aug 29:  Women who are genetically predisposed to the risk of Alzheimer’s are more susceptible to developing the disease during a critical 10-year span in their lives than men with similar genetic risks, researchers have found.

The findings showed that among women and men between ages 65 and 75 having one copy of ApoE4, women — more than 10 years after the start of menopause — were at increased risk compared with men.

The study contradicts the previously held view that women with one copy of Apolipoprotein E4 allele (ApoE4) — the main genetic risk factor for late-onset Alzheimer — were diagnosed with the disease 50 per cent more often than men with the same genetic profile.

The reasons that might underlie these sex differences could be linked to physiologic changes associated with menopause and estrogen loss, the researchers said in the paper published in the journal JAMA Neurology.

“Menopause and plummeting estrogen levels, which on average begins at 51, may account for the difference,” said Judy Pa, Assistant Professor at the University of Southern California, Los Angeles.

For the study, the team analysed 27 research studies with data on nearly 58,000 participants, between the ages of 55 and 85, to determine how sex and APOE genotype affect the risks for developing mild cognitive impairment (MCI) — often the transitional phase from cognitively normal ageing to dementia, and Alzheimer’s.

Further, women also appeared to be at increased risk of developing Alzheimer’s between the ages of 55 and 70 compared to men.

“Collectively, our findings, along with previous work, warrant further investigation into a likely complex set of risk factors with consideration of sex-specific treatments for cognitive decline and Alzheimer’s disease,” said Arthur W. Toga, from the varsity.

“For example, if women are at increased risk for AD at younger ages, it is plausible that treatments for women may need to be initiated earlier, especially in those who carry an APOE E4 allele.”

IANS

Disaster

Coronavirus crisis may get ‘worse and worse and worse’, warns WHO

Published

on

Tedros Adhanom Ghebreyesus WHO

GENEVA : The raging coronavirus pandemic has the potential to get far worse if all nations do not adhere to basic healthcare precautions, the World Health Organization (WHO) warned on Monday.

“Let me be blunt, too many countries are headed in the wrong direction, the virus remains public enemy number one,” Director General Tedros Adhanom Ghebreyesus told a virtual briefing from WHO headquarters in Geneva.

“If basics are not followed, the only way this pandemic is going to go, it is going to get worse and worse and worse. But it does not have to be this way.”

Infections rose above 13 million across the world on Monday, according to a Reuters tally, climbing by one million in just five days in a pandemic that has killed more than half a million people.

Continue Reading

Cities

Doctor who managed Goa’s only Covid hospital tests positive

The state currently has more than 900 active Covid-19 cases, with 17 fatalities linked to coronavirus.

Published

on

Dr Gomes

Panaji, July 13 : Dr. Edwin Gomes, who had emerged as the face of Goa”s Covid-19 treatment and care effort, and had served as the in-charge of medication of patients at the state’s only designated Covid-19 hospital, has tested positive for the viral infection, a government spokesperson said.

“Dr. Gomes has been admitted to a state government facility for doctors infected by coronavirus,” the spokesperson said.

Gomes, 58, is also the head of medicine at the state”s only medical college, the Goa Medical College, and had last week ended his unbroken 98-day shift at the designated Covid-19 hospital.

The state currently has more than 900 active Covid-19 cases, with 17 fatalities linked to coronavirus.

Chief Minister Pramod Sawant has said that “four to five” Covid-19 patients who died, were suffering from cancer. “Eight to 10 patients were above the age of 80 years, while one also died of liver failure. The death rate has increased due to co-morbid conditions,” Sawant told reporters at the State Secretariat.

Continue Reading

Disaster

Glenmark cuts Fabiflu price by 27%

On June 20, Glenmark announced that it received manufacturing and marketing approval from India”s drug regulator for FabiFlu, making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19.

Published

on

By

Glenmark Fabiflu

New Delhi, July 13 : Glenmark Pharmaceuticals has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 Covid patients that are prescribed with the oral antiviral.

Further, Glenmark has announced a price reduction of 27 per cent for FabiFlu. The new MRP is Rs 75 per tab from the earlier Rs 103 per tab.

The price reduction has been made possible through benefits gained from higher yields and better scale, as both the API and formulations are made at Glenmark”s facilities in India, the benefits of which are being passed on to patients in the country.

Glenmark has successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu through its own in-house R&D team within the country, ensuring self-reliance with regard to long term production and manufacturing.

Commenting on these developments, Alok Malik, Senior Vice President & Head – India business, Glenmark Pharmaceuticals said, “We expect this post marketing surveillance study to shed more light on the drug”s clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu. Our priority from the start of this pandemic has been to offer patients in India an effective treatment for COVID-19, while also ensuring accessibility to the masses.

“Our internal research shows us that we launched FabiFlu in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country.”

Despite investing significantly in R&D, clinical trials and the manufacturing of FabiFlu (API and formulations), Glenmark has managed to keep the pricing of FabiFlu lower as compared to its price in other countries.

FabiFlu in India was originally launched at Rs 103 per tablet, while, its price in Indian Rupees is higher in the remaining countries like Rs 600 in Russia, Rs 378 in Japan, Rs 350 in Bangladesh and Rs 215 in China.

On June 20, Glenmark announced that it received manufacturing and marketing approval from India”s drug regulator for FabiFlu, making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19.

The manufacturing and marketing approval was granted as part of accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India. The approval”s restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Continue Reading
Advertisement

Most Popular